Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Edwards Lifesciences (EW) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareEW

Closing price · Nov 19, 2026 $103.72 -1.4% on the day · +20.6% over 12 months 52-week range $75.87 – $107.15
Get EW alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling9last 12 months
Reported sales$34.1M36 of 58 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Feb 15, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Daniel J. Lippis, Cvp, Tavr sold 619 shares at $104.25 ($65K).

Trade date
Nov 10, 2026
Disclosed to the SEC
Nov 10, 2026
Type
Pre-planned sale, 10b5-1 (code S)

Read the original SEC filing ↗All EW insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

EW insider transactions (Form 4)

Open-market purchases and sales. 107 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 10SEC Daniel J. LippisCvp, Tavr Sell Plan 61940,034 held (−2%) $104.25 $65K -0.5% —
Nov 9SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell Plan 48,90022,798 held (−68%) $103.05 $5.0M +0.6% —
Nov 9SEC Bernard J. ZovighianCEO Sell Plan 13,91698,845 held (−12%) $102.78 $1.4M +0.9% —
Nov 9SEC Bernard J. ZovighianCEO Sell Plan 9,184112,761 held (−8%) $103.39 $949K +0.3% —
Oct 8SEC Daniel J. LippisCvp, Tavr Sell Plan 61940,034 held (−2%) $85.65 $53K +21.1% —
Sep 11SEC Daniel J. LippisCvp, Tavr Sell Plan 61940,034 held (−2%) $87.51 $54K +18.5% —
Aug 31SEC Andrew M. DahlSvp, Corporate Controller Sell 54414,868 held (−4%) $91.06 $50K +13.9% —
Aug 28SEC Annette BrulsCvp, Emeacla Sell 2,64417,984 held (−13%) $89.98 $238K +15.3% —
Aug 26SEC Daveen ChopraCvp, Tmtt, Surgical & Ihfm Sell 30,64644,324 held (−41%) $90.99 $2.8M +14.0% —
Aug 26SEC Wayne MarkowitzCvp, Japac Sell 1,24020,294 held (−6%) $91.47 $113K +13.4% —
Aug 26SEC Daveen ChopraCvp, Tmtt, Surgical & Ihfm Sell 1,15474,970 held (−2%) $91.76 $106K +13.0% —
Aug 11SEC Daniel J. LippisCvp, Tavr Sell Plan 61940,034 held (−2%) $92.03 $57K +12.7% —
Jul 30SEC Wayne MarkowitzCvp, Japac Sell 14621,534 held (−1%) $86.03 $13K +20.6% —
Jul 28SEC Wayne MarkowitzCvp, Japac Sell 9,62821,680 held (−31%) $85.06 $819K +21.9% —
Jul 27SEC Bernard J. ZovighianCEO Sell 2,9218,916 held (−25%) $83.93 $245K +23.6% —
Jul 10SEC Daniel J. LippisCvp, Tavr Sell Plan 61940,034 held (−2%) $91.70 $57K +13.1% —
Jun 30SEC Daniel J. LippisCvp, Tavr Sell Plan 61940,411 held (−2%) $91.40 $57K +13.5% —
Jun 17SEC Bernard J. ZovighianCEO Sell Plan 52311,517 held (−4%) $87.92 $46K +18.0% —
May 29SEC Andrew M. DahlSvp, Corporate Controller Sell 56815,334 held (−4%) $86.08 $49K +20.5% —
May 27SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell 23,14598,611 held (−19%) $86.42 $2.0M +20.0% —
May 22SEC Daveen ChopraCvp, Tmtt & Surgical Sell 1,50044,324 held (−3%) $84.60 $127K +22.6% —
May 18SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell 9,96822,798 held (−30%) $82.07 $818K +26.4% —
May 18SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell 8,00030,970 held (−21%) $81.82 $655K +26.8% —
May 18SEC Daniel J. LippisCvp, Tavr Sell Plan 62040,411 held (−2%) $81.14 $50K +27.8% —
May 12SEC Bernard J. ZovighianCEO Sell Plan 35,50612,040 held (−75%) $77.92 $2.8M +33.1% —
May 12SEC Bernard J. ZovighianCEO Sell Plan 84547,546 held (−2%) $78.40 $66K +32.3% —
May 11SEC Wayne MarkowitzCvp, Japac Sell 59321,680 held (−3%) $79.73 $47K +30.1% —
May 4SEC Daniel J. LippisCvp, Tavr Sell Plan 1,01933,682 held (−3%) $83.98 $86K +23.5% —
May 4SEC Daniel J. LippisCvp, Tavr Sell Plan 1,00033,934 held (−3%) $82.99 $83K +25.0% —
May 4SEC Daniel J. LippisCvp, Tavr Sell Plan 1934,934 held (−0%) $83.99 $2K +23.5% —
Apr 9SEC Scott B. UllemCFO Sell Plan 8,32439,699 held (−17%) $79.79 $664K +30.0% —
Apr 9SEC Scott B. UllemCFO Sell Plan 4,67648,023 held (−9%) $80.50 $376K +28.9% —
Apr 6SEC Daniel J. LippisCvp, Tavr Sell Plan 1,01933,934 held (−3%) $80.98 $83K +28.1% —
Apr 2SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell Plan 18,00421,266 held (−46%) $80.05 $1.4M +29.6% —
Apr 2SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell Plan 4,67639,270 held (−11%) $80.59 $377K +28.7% —
Mar 11SEC Scott B. UllemCFO Sell Plan 7,90139,699 held (−17%) $85.21 $673K +21.7% —
Mar 11SEC Scott B. UllemCFO Sell Plan 5,09947,600 held (−10%) $84.46 $431K +22.8% —
Mar 11SEC Daniel J. LippisCvp, Tavr Sell Plan 1,01933,934 held (−3%) $85.38 $87K +21.5% —
Mar 2SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell Plan 11,34021,266 held (−35%) $85.93 $974K +20.7% —
Feb 26SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell 24,00021,266 held (−53%) $83.84 $2.0M +23.7% —
Feb 13SEC Bernard J. ZovighianCEO Sell 19,89883,896 held (−19%) $76.61 $1.5M +35.4% —
Feb 13SEC Bernard J. ZovighianCEO Sell 2,532103,794 held (−2%) $77.13 $195K +34.5% —
Jan 9SEC Daniel J. LippisCvp, Tavr Sell Plan 1,01922,002 held (−4%) $85.70 $87K +21.0% —
Jan 6SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell Plan 8,70831,870 held (−21%) $85.98 $749K +20.6% —
Jan 6SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell Plan 2,63240,578 held (−6%) $84.62 $223K +22.6% —
Dec 12SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell 5,90038,970 held (−13%) $83.74 $494K +23.9% —
Dec 12SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell 5,48644,870 held (−11%) $83.79 $460K +23.8% —
Dec 12SEC Heisz Leslie StoneDirector Sell 2,61530,948 held (−8%) $83.41 $218K +24.3% —
Dec 12SEC Daniel J. LippisCvp, Japac Sell Plan 1,01922,002 held (−4%) $84.03 $86K +23.4% —
Dec 11SEC Daveen ChopraCvp, Tmtt & Surgical Sell 2,00032,201 held (−6%) $84.38 $169K +22.9% —
Dec 10SEC Bernard J. ZovighianCEO Sell Plan 21,48784,839 held (−20%) $85.21 $1.8M +21.7% —
Dec 10SEC Donald E. Bobo Jr.Cvp,Strategy/Corp Development Sell Plan 11,34050,356 held (−18%) $83.83 $951K +23.7% —
Dec 10SEC Bernard J. ZovighianCEO Sell Plan 3,8638,597 held (−31%) $83.45 $322K +24.3% —
Dec 9SEC Scott B. UllemCFO Sell Plan 7,70039,898 held (−16%) $84.47 $650K +22.8% —
Dec 8SEC Wayne MarkowitzCvp, Japac Sell 58317,563 held (−3%) $86.01 $50K +20.6% —
Nov 10SEC Scott B. UllemCFO Sell Plan 10,02639,898 held (−20%) $83.02 $832K +24.9% —
Nov 10SEC Scott B. UllemCFO Sell Plan 2,97449,924 held (−6%) $83.30 $248K +24.5% —
Nov 10SEC Daniel J. LippisCvp, Japac Sell Plan 1,02022,002 held (−4%) $82.55 $84K +25.7% —
Historical context

Similar past setups: not applicable. EW has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with EW in the Research Lab

EW has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

EW closeInsider buyInsider sale
708090100110DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-02-10EEarnings release filed 2026-04-23EEarnings release filed 2026-07-23EEarnings release filed 2026-11-04Sold $12,588 on 2026-07-30 · Wayne MarkowitzSold $45,982 on 2026-06-17 · Bernard J. ZovighianSold $47,280 on 2026-05-11 · Wayne MarkowitzSold $48,853 on 2026-05-29 · Andrew M. DahlSold $49,534 on 2026-08-31 · Andrew M. DahlSold $50,307 on 2026-05-18 · Daniel J. LippisSold $53,017 on 2026-10-08 · Daniel J. LippisSold $54,169 on 2026-09-11 · Daniel J. LippisSold $56,577 on 2026-06-30 · Daniel J. LippisSold $56,762 on 2026-07-10 · Daniel J. LippisSold $56,967 on 2026-08-11 · Daniel J. LippisSold $64,531 on 2026-11-10 · Daniel J. LippisSold $82,523 on 2026-04-06 · Daniel J. LippisSold $84,585 on 2026-05-01 · Daniel J. LippisSold $85,576 on 2026-05-04 · Daniel J. LippisSold $87,332 on 2026-01-09 · Daniel J. LippisSold $126,905 on 2026-05-22 · Daveen ChopraSold $168,750 on 2025-12-11 · Daveen ChopraSold $237,907 on 2026-08-28 · Annette BrulsSold $245,134 on 2026-07-27 · Bernard J. ZovighianSold $650,412 on 2025-12-09 · Scott B. UllemSold $818,958 on 2026-07-28 · Wayne MarkowitzSold $971,429 on 2026-01-06 · Donald E. Bobo Jr.Sold $974,430 on 2026-03-02 · Donald E. Bobo Jr.Sold $1,040,544 on 2026-04-09 · Scott B. UllemSold $1,190,900 on 2026-03-11 · Daniel J. Lippis, Scott B. UllemSold $1,257,493 on 2025-12-12 · Daniel J. Lippis, Donald E. Bobo Jr., Heisz Leslie StoneSold $1,272,949 on 2025-12-10 · Bernard J. Zovighian, Donald E. Bobo Jr.Sold $1,472,678 on 2026-05-15 · Donald E. Bobo Jr.Sold $1,719,741 on 2026-02-12 · Bernard J. ZovighianSold $1,818,055 on 2026-04-02 · Donald E. Bobo Jr.Sold $1,881,150 on 2025-12-08 · Bernard J. Zovighian, Wayne MarkowitzSold $2,000,193 on 2026-05-27 · Donald E. Bobo Jr.Sold $2,012,076 on 2026-02-25 · Donald E. Bobo Jr.Sold $2,833,013 on 2026-05-12 · Bernard J. ZovighianSold $3,007,856 on 2026-08-26 · Daveen Chopra, Wayne MarkowitzSold $7,419,091 on 2026-11-09 · Bernard J. Zovighian, Donald E. Bobo Jr.
Bought, 12 months$0
Sold, 12 months$34.1M
Insiders buying0
Insiders selling9

Edwards Lifesciences insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $34.1M of EW stock on the open market; P/E 55.8 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

EW insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $6.4M sold (13 trades)Q4 2025Q1 2026: $7.0M sold (10 trades)Q1 2026Q2 2026: $9.8M sold (19 trades)Q2 2026Q3 2026: $4.5M sold (11 trades)Q3 2026Q4 2026: $7.5M sold (5 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$7.5M5
Q3 2026—0$4.5M11
Q2 2026—0$9.8M19
Q1 2026—0$7.0M10
Q4 2025—0$6.4M13

Valuation, profit and volume

P/E (trailing)55.8Sector median 25.0
Volume vs. 50-day0.9×Last 5 sessions

Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Edwards Lifesciences insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $34.1M. Among insiders with enough purchase history to measure, Paul A. Laviolette (Director) has the highest Insider Score at 100. 36 of 58 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

EW earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Nov 4, 2026 +9.1% Sold $53K +5.9%S&P -2.8% pending
Jul 23, 2026 -11.0% Sold $113K -2.1%S&P -1.1% +8.7%
Apr 23, 2026 +0.9% Sold $2.9M +3.2%S&P +0.4% +1.9%
Feb 10, 2026 -8.2% None +3.3%S&P -0.3% +3.1%
Oct 30, 2025 +12.7% None -0.3%S&P -0.8% +5.1%
Jul 24, 2025 +0.7% None +4.0%S&P +0.5% +2.3%
Apr 23, 2025 +2.3% None +6.4%S&P +3.7% -0.2%
Feb 11, 2025 +3.1% None +6.6%S&P -0.2% -8.6%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

EW short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 47% of volume sold short2026-08-27: 29% of volume sold short2026-08-28: 53% of volume sold short2026-08-31: 51% of volume sold short2026-09-01: 44% of volume sold short2026-09-02: 41% of volume sold short2026-09-03: 44% of volume sold short2026-09-04: 27% of volume sold short2026-09-08: 47% of volume sold short2026-09-09: 44% of volume sold short2026-09-10: 55% of volume sold short2026-09-11: 43% of volume sold short2026-09-14: 42% of volume sold short2026-09-15: 38% of volume sold short2026-09-16: 49% of volume sold short2026-09-17: 56% of volume sold short2026-09-18: 51% of volume sold short2026-09-21: 38% of volume sold short2026-09-22: 31% of volume sold short2026-09-23: 45% of volume sold short2026-09-24: 44% of volume sold short2026-09-25: 38% of volume sold short2026-09-28: 41% of volume sold short2026-09-29: 63% of volume sold short2026-09-30: 56% of volume sold short2026-10-01: 40% of volume sold short2026-10-02: 57% of volume sold short2026-10-05: 41% of volume sold short2026-10-06: 52% of volume sold short2026-10-07: 38% of volume sold short2026-10-08: 81% of volume sold short2026-10-09: 63% of volume sold short2026-10-12: 65% of volume sold short2026-10-13: 63% of volume sold short2026-10-14: 65% of volume sold short2026-10-15: 56% of volume sold short2026-10-16: 51% of volume sold short2026-10-19: 53% of volume sold short2026-10-20: 43% of volume sold short2026-10-21: 45% of volume sold short2026-10-22: 43% of volume sold short2026-10-23: 54% of volume sold short2026-10-26: 39% of volume sold short2026-10-27: 38% of volume sold short2026-10-28: 39% of volume sold short2026-10-29: 36% of volume sold short2026-10-30: 35% of volume sold short2026-11-02: 50% of volume sold short2026-11-03: 49% of volume sold short2026-11-04: 30% of volume sold short2026-11-05: 44% of volume sold short2026-11-06: 47% of volume sold short2026-11-09: 44% of volume sold short2026-11-10: 57% of volume sold short2026-11-11: 42% of volume sold short2026-11-12: 63% of volume sold short2026-11-13: 57% of volume sold short2026-11-16: 53% of volume sold short2026-11-17: 33% of volume sold short2026-11-18: 37% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 37%20-day average: 45%Prior 2 months: 49%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded EW

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 27, 2026Jul 21, 2026 +30.7%

Insiders at Edwards Lifesciences

InsiderBoughtSoldLast filingPast buys beat S&PScore
Donald E. Bobo Jr.Cvp,Strategy/Corp Development — $16.2M Nov 9, 2026 — —
Bernard J. ZovighianCEO — $9.4M Nov 9, 2026 — —
Scott B. UllemCFO — $3.9M May 11, 2026 — —
Daveen ChopraCvp, Tmtt, Surgical & Ihfm — $3.2M Sep 11, 2026 — —
Wayne MarkowitzCvp, Japac — $1.0M Sep 14, 2026 — —
Daniel J. LippisCvp, Tavr — $989K Nov 10, 2026 — —
Annette BrulsCvp, Emeacla — $238K Aug 28, 2026 — —
Heisz Leslie StoneDirector — $218K May 8, 2026 — —
Andrew M. DahlSvp, Corporate Controller — $98K Nov 13, 2026 — —
Theodora MistrasCFO — — Jul 10, 2026 — —
Leslie C. DavisDirector — — May 8, 2026 — —
David T. FeinbergDirector — — May 8, 2026 — —
Kieran GallahueDirector — — May 8, 2026 — —
Paul A. LavioletteDirector — — May 8, 2026 — 100
Steven R. LorangerDirector — — May 8, 2026 — —
Ramona SequeiraDirector — — May 8, 2026 — —
Nicholas J. ValerianiDirector — — May 8, 2026 — —

Board links: companies that share insiders with EW

Directors and executives who filed Form 4s for EW and another company in the last 12 months.

See the map →
  • HUMHumana David T. Feinberg Director here · Director at HUM · latest filing May 8, 2026
  • ILMNIllumina Scott B. Ullem CFO here · Director at ILMN · latest filing Oct 2, 2026
  • PLSEPulse Biosciences Paul A. Laviolette Director here · CEO at PLSE · latest filing May 11, 2026
  • VTRSViatris Theodora Mistras CFO here · CFO at VTRS · latest filing Jul 10, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

EW stock: common questions

Are Edwards Lifesciences insiders buying EW stock?

No. No Edwards Lifesciences insider reported an open-market purchase of EW in the past 12 months.

Are Edwards Lifesciences insiders selling EW stock?

9 insiders reported sales worth $34.1M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is EW's P/E ratio?

EW trades at about 55.8 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is EW's 52-week range?

Over the past year EW has traded between $75.87 and $107.15. It last closed at $103.72 on Nov 19, 2026.